Sparfloxacinの抗酸菌感染症治療薬としての可能性
スポンサーリンク
概要
- 論文の詳細を見る
We studied the therapeutic potential of utilizing sparfloxacin (SPFX), a newly developed quinolone, to prevent various mycobacterial infections. The in vitro activity of SPFX as a preventive agent for various mycobacteria was determined using the actual countmethod on Ogawa egg medium. The minimal inhibitory concentrations (MIC<SUB>s</SUB>) of SPFXwere as follows: of loxacin-sensitive M. tuberculosis, 0.16-0332μEg/ml; ofloxacin- resistant M. tuberculosis, 0.63-2.5μEg/ml; M. avium; 0.63-10μEg/ml (MICs were equalor less than 1.25μEg/ml in seven out of 11 strains); M. intracellulare, 2.5-10μEg/ml (MICswere equal or more than 10μ/ml in 17 out of 23 strains); M. kansasii, ≥0.08μg/ml; M. chelonae subsp. abscessus, 1.25μg/ml; M. chelonaesubsp. chelonae, 0.63μg/ml; M. scrofulaceum, μg/ml; M. nonchromogenicum, 1.25μg/ml; M. xenopi, ≥0.08μ/ml; M. gordonae, ≥0.08μg/ml. The average serumconcentrations of SPFX during the period of multiple oral administration (200 mg once aday) were 0.35±0.16μg/ml before administration, 0.67±0.32μg/ml after one hour, 1.13±0.21μEg/ml after two hours, 1.27±0.32μg/ml after four hours and 1.31±0.34μg/ml aftersix hours. These results indicate that SPFX has a strong therapeutic potential to preventinfections due to M. tuberculosis, M. kansasii, M. fortuitum, M. chelonae subsp. chelonae, M. scrofulaceum, M.xenopi and M. gordonae. Moreover, it may be expected to be apromising agent against infections due to ofloxacin-resistant M. tuberculosis, M. aviumand M. nonchromogenicum
論文 | ランダム
- ルカ・ブッタロ 「保険利益論」 (2) (法学部国際関係法学科開設10周年記念)
- 翻訳 ルカ・ブッタロ『保険利益論』(3・完)
- ルカ・ブッタロ「保健利益論」(一)
- 遺言による保険金受取人変更の可否 (佐藤幸夫名誉教授古稀記念論集)
- 傷害保険契約における偶然性の立証責任